NY-ALVAREZ-&-MARSAL
30.1.2024 10:16:29 CET | Business Wire | Press release
Leading global professional services firm Alvarez & Marsal (A&M) announced the appointment of Stockholm-based Annika Melin Jakobsson and New York-based Patricia Alonso de la Fuente as Global Transaction Advisory Group (TAG) Managing Directors within its Capital Markets & Accounting Advisory (CMAA) practice. Ms. Melin Jakobsson will develop A&M’s CMAA offering in the Nordics and EMEA. Ms. Alonso de la Fuente will support CMAA in the US, Spain and its continued Latin American (LatAm) expansion.
Paul Aversano, Global Practice Leader of A&M’s Global Transaction Advisory Group, said, “Building our CMAA offering in the Nordics and EMEA while expanding it across LatAm and Spanish speaking countries enhances our independent capital markets and advisory accounting advice capabilities for private equity (PE) and multinational corporate clients seeking transaction support. Following on CMAA Managing Director Ayres Moura’s recent hire, Annika’s and Patricia’s joining aligns with our strategic talent, capabilities, and geographic growth plan.”
Ms. Melin Jakobsson, A&M’s Nordic CMAA practice Leader who will support this offering across EMEA, specializes in initial public offerings (IPO), carve-outs, capital markets transactions, corporate governance, risk, compliance, and all mergers and acquisitions (M&A) lifecycle aspects. She advises board and management teams, in listed and non-listed companies, and has led national and international large- mid- and small cap IPOs and capital markets transactions. Ms. Melin Jakobsson ensures clients’ IPO readiness, and once listed, their alignment with capital markets’ governance, risk and compliance and financial reporting requirements.
Ms. Alonso de la Fuente’s global mindset and local expertise crisscrosses her extensive cross-border and cross-functional market transaction experience. She focuses on IPOs, acquisitions, divestitures, international financial reporting standards (IFRS), US generally accepted accounting principles (GAAP) conversions and complex technical accounting matters. Additionally, she has led complex, cross-functional M&A and IPO projects and developed holistic solutions for clients across diverse sectors in the Americas and Europe.
Phil Mitchell, EMEA TAG Practice Co-Leader, noted, “A&M’s freedom from audit conflicts and integrated platform enables independent capital markets and accounting advice that maximizes value for PE and corporate clients. Annika’s and Patricia’s combined expertise solidifies our global CMAA offering and elevates our exit readiness capabilities.”
Previously, Ms. Melin Jakobsson served as Managing Partner for EY’s Nordic Capital Markets group and Managing Partner for KPMG’s Deal Advisory Capital Markets Group in Sweden. While at KPMG, she also served as a member of its board of directors.
Prior to joining A&M, Ms. Alonso de la Fuente served with KPMG, most recently as Partner in Deal Advisory in New York, along with leading that firm’s Capital Markets and Accounting Advisory Services US-LatAm corridor.
Mses. Melin Jakobsson and Alonso de la Fuente, said, “Capital markets are part of the transaction lifecycle. With tailored teams to meet needs and demands, A&M’s business model supports clients wherever we are in that cycle. Across the transaction spectrum, from aligning IPO readiness to planning exits, now is the time for corporates and PE to prepare.”
Ms. Melin Jakobsson earned a master’s degree in law from Uppsala University and has been part of the Swedish Nasdaq Listing Auditor’s team for 10+ years. She has been engaged as a capital market specialist by the Swedish Institute for the Accountancy Profession, Accountancy Europe and the Centre for Business and Policy Studies.
Ms. Alonso de la Fuente holds a bachelor’s degree in business administration from Complutense University, Madrid, and Leeds, United Kingdom.
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 9,000 people across six continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what is really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
About Alvarez & Marsal Global Transaction Advisory Group
A&M’s Global Transaction Advisory Group provides investors and lenders the answers needed to get the deal done. We combine our firm’s deep operational, industry and functional resources with Big Four-quality financial accounting and tax expertise to assess key deal drivers and focus on the root cause of any critical deal issues. As the largest transaction advisory practice outside the Big Four, our global integrated teams help private equity, sovereign wealth funds, family offices and hedge funds as well as corporate acquirers unlock value across the investment lifecycle.
The firm’s Global Transaction Advisory Group includes over 950 professionals in 37 offices worldwide. Our global team has extensive industry knowledge across multiple sectors and is free from audit-based conflicts of interests.
To learn more, visit: AlvarezandMarsal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122439270/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
